NASDAQ:IRIX

IRIDEX Stock Forecast, Price & News

$6.54
-0.09 (-1.36 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.44
$6.68
50-Day Range
$6.29
$7.91
52-Week Range
$1.60
$9.71
Volume15,497 shs
Average Volume42,103 shs
Market Capitalization$103.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27
30 days | 90 days | 365 days | Advanced Chart
Receive IRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.


IRIDEX logo

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.65 out of 5 stars

Computer And Technology Sector

488th out of 1,649 stocks

Electromedical Equipment Industry

17th out of 65 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











IRIDEX (NASDAQ:IRIX) Frequently Asked Questions

Is IRIDEX a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRIDEX stock.
View analyst ratings for IRIDEX
or view top-rated stocks.

What stocks does MarketBeat like better than IRIDEX?

Wall Street analysts have given IRIDEX a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IRIDEX wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting IRIDEX?

IRIDEX saw a decrease in short interest in June. As of June 15th, there was short interest totaling 157,200 shares, a decrease of 42.7% from the May 31st total of 274,300 shares. Based on an average daily volume of 81,100 shares, the short-interest ratio is presently 1.9 days. Approximately 1.2% of the company's stock are sold short.
View IRIDEX's Short Interest
.

When is IRIDEX's next earnings date?

IRIDEX is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for IRIDEX
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) issued its quarterly earnings data on Tuesday, May, 11th. The medical equipment provider reported ($0.14) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.14). The medical equipment provider had revenue of $11.96 million for the quarter, compared to the consensus estimate of $9.90 million. IRIDEX had a negative net margin of 17.02% and a negative trailing twelve-month return on equity of 33.84%.
View IRIDEX's earnings history
.

How has IRIDEX's stock price been impacted by COVID-19?

IRIDEX's stock was trading at $1.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IRIX stock has increased by 232.0% and is now trading at $6.54.
View which stocks have been most impacted by COVID-19
.

What guidance has IRIDEX issued on next quarter's earnings?

IRIDEX issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $48 million-51 million, compared to the consensus revenue estimate of $50.74 million.

What price target have analysts set for IRIX?

1 analysts have issued 1 year target prices for IRIDEX's stock. Their forecasts range from $11.00 to $11.00. On average, they expect IRIDEX's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 68.2% from the stock's current price.
View analysts' price targets for IRIDEX
or view top-rated stocks among Wall Street analysts.

Who are IRIDEX's key executives?

IRIDEX's management team includes the following people:
  • Mr. David I. Bruce, Pres, CEO & Director (Age 62, Pay $456.73k)
  • Mr. Fuad Ahmad, Interim Chief Financial Officer (Age 51, Pay $664.5k)
  • Mr. Patrick Mercer, Chief Operating Officer (Age 49, Pay $368.53k)
  • Ms. Leigh Salvo, Head of Investor Relations

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?

7 employees have rated IRIDEX CEO Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among IRIDEX's employees.

Who are some of IRIDEX's key competitors?

What other stocks do shareholders of IRIDEX own?

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

How do I buy shares of IRIDEX?

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $6.54.

How much money does IRIDEX make?

IRIDEX has a market capitalization of $103.07 million and generates $36.35 million in revenue each year. The medical equipment provider earns $-6,330,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does IRIDEX have?

IRIDEX employs 89 workers across the globe.

What is IRIDEX's official website?

The official website for IRIDEX is www.iridex.com.

Where are IRIDEX's headquarters?

IRIDEX is headquartered at 1212 Terra Bella Avenue, Mountain View CA, 94043.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]


This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]om | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.